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IL-6The A2B adenosine receptor (A2B AR), activated in response to high levels of endogenous adenosine, is the major
AR subtype involved inmesenchymal stem cell (MSC) differentiation to osteoblasts and bone formation. For this
reason, targeting of A2B AR with selective allosteric modulators may represent a promising pharmacological
approach to the treatment of bone diseases.
Herein, we report the characterization of a 3-keto-indole derivative, 2-(1-benzyl-1H-indol-3-yl)-2-oxo-N-
phenylacetamide (KI-7), as A2B AR positive allosteric modulator in MSCs, demonstrating that this compound is
able to potentiate the effects of either adenosine and synthetic orthosteric A2B AR agonists in mediating
osteoblast differentiation in vitro. In detail, we observed that MSC treatment with KI-7 determined an increase
in the expression of osteoblast-related genes (Runx2 and osterix) and osteoblast marker proteins (phosphatase
alkaline and osteocalcin), associated with a stimulation of osteoblast mineralization.
In the early phase of differentiation programme, KI-7 signiﬁcantly potentiated physiological and A2B AR agonist-
mediated down-regulation of IL-6 release. Conversely, during the late stage of differentiation, when most of the
cells have an osteoblast phenotype, KI-7 caused a sustained raise in IL-6 levels and an improvement in osteoblast
viability. These data suggest that a positive allosteric modulation of A2B AR not only favours MSC commitment to
osteoblasts, but also ensures a greater survival of mature osteoblasts. Our study paves the way for a therapeutic
use of selective positive allosteric modulators of A2B AR in the control of osteoblast differentiation, bone
formation and fracture repair.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Bone health is a chief medical concern for the ageing population, be-
cause deterioration of the bone is signiﬁcantly correlated with fracture,
disease, and a diminished quality of life [1]. With ageing, bone mass
tends to decrease, resulting in the onset of many diseases associated
with bone loss. For example, osteoporosis, characterized by low bone
mass and structural deterioration of bone tissue with an increased sus-
ceptibility to fractures, is amajor public health threat to the elderly [2,3].
A deeper understanding of themechanisms by which bone formation is
physiologically regulated is the goal of many studies aimed at ﬁnding
adequate treatments of all the bone loss diseases. The majority of ther-
apies for osteoporosis are largely based on preventing bone loss by
inhibiting osteoclast-mediated bone resorption [4,5]. As regeneration
of trabecular architecture by bone-forming osteoblasts (OBs) is requiredniversity of Pisa, Via Bonanno 6,
50 2219609.to fully restore the mechanical integrity of bone, there is much interest
in developing anabolic agents to stimulate de novo bone formation [6].
Recently, an emerging role for purine receptors, and in particular for
the A2B adenosine receptor (AR) subtype, in controlling osteoblast dif-
ferentiation has been outlined [7–11]. A2B AR is expressed in MSCs
and/or osteoblast progenitors and is activated when adenosine levels
raise up to micromolar concentrations resulting from ATP degradation
during bone injury [12,13]. A2B AR activation promotes the expression
of the osteogenic factor Runx2 and phosphatase alkaline (ALP),
favouring mesenchymal stem cell (MSC) differentiation to osteoblasts
[8]. These data suggest that A2B AR may represent an interesting new
target in the treatment of osteoporosis.
Therapies using receptor agonists are often prone to side effects,
owing to the widespread distribution of the target receptor in the
body. Allosteric modulation of membrane receptors has been intensive-
ly studied in the past three decades and is now considered an important
mechanism for the control of receptor functions. A signiﬁcant advantage
of a therapy based on a positive allosteric modulator of a membrane re-
ceptor over its native, orthosteric activator is that, in principle, a greater
tolerability can be achieved [14,15]. Particularly, a positive allosteric
2958 M.L. Trincavelli et al. / Biochimica et Biophysica Acta 1843 (2014) 2957–2966modulator is expected to enhance the action of the endogenous agonist
without effects of its own on the unoccupied receptor. As a conse-
quence, the effects of the endogenous agonist, which might be thera-
peutically insufﬁcient in a particular disease state, could be magniﬁed
through allosteric modulation. An increasing percentage of G Protein-
Coupled Receptors (GPCRs), including ARs, has been found to bemodu-
lated allosterically by various compounds [16–20].
Recently, we have developed and characterized a new series of
1-benzyl-3-ketoindoles as the ﬁrst class of positive/negative allosteric
modulators of the human A2B AR [21,22].
Subsequently, we investigated whether one of these positive A2B AR
allosteric modulators, namely 2-(1-benzyl-1H-indol-3-yl)-2-oxo-N-
phenylacetamide (KI-7) could markedly potentiate orthosteric agonist
efﬁcacy, so as to accelerate agonist-mediated osteoblast differentiation
byMSC precursors. The results of our study suggest that this compound
may represent a prototype of an innovative class of pharmacological
agents useful to control disorders where bone destruction exceeds
bone formation (e.g. osteoporosis, rheumatoid arthritis, osteogenesis
imperfecta, multiple myeloma, fracture mal-union).
2. Materials and methods
2.1. Materials
Human bone marrow MSCs and cell culture medium were
purchased by Lonza (Milan, Italy). Adenosine receptor ligands,
5′-N-ethylcarboxamidoadenosine (NECA), 2-[6-amino-3,5-dicyano-
4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-ylsulfanyl]acetamide
(BAY 60-6583), and N-(4-acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-
2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide
(MRS1706) were purchased by Tocris Bioscience (Bristol, UK).
RNeasy® Mini Kit was purchased from Qiagen S.p.A. The Script
cDNA synthesis kit was furnished by Bio-rad s.r.l. Fluocycle® II
SYBR® was obtained from Euroclone s.p.a. (Milan, Italy). KI-7 was
synthesized as previously reported [21].
2.2. Cell cultures
MSCs were cultured in normal growth medium (MSCGM, Lonza),
plated (5 × 103 cells/cm2) in 75-cm2 ﬂasks and incubated at 37 °C in
5% CO2 and 95% air. The medium was changed to remove nonadherent
cells every 3 to 4 days, and the cells were used at passages 0 to 3.
For osteoblast differentiation studies, cells were seeded (3
× 103 cells/cm2) in normal growth medium and, 24 h later, the me-
dium was changed with osteogenic induction medium [8] containing
dexamethasone (10−8 M), L-glutamine, ascorbate (50 μg/mL),
penicillin/streptomycin (2 mM) and β-glycerophosphate (2 mM).
2.3. Measurement of cAMP levels in MSCs
MSCs were plated in 24-well plates in 0.5 mL of growth medium.
After 24 h, the medium was changed with osteogenic induction
medium, and the cells were differentiated for different days. At each
time of differentiation, cells were incubated at 37 °C for 15 min with
noncomplete medium containing 20 μM of the phosphodiesterase in-
hibitor 4-[(3-butoxy-4-methoxyphenyl)-methyl]-2-imidazolidinone
(Ro 20-1724), and adenosine deaminase (ADA, 1 U/mL). Cells
were then treated for 15 min with different AR orthosteric agonists
(BAY 60-6583, selective for the A2B AR, NECA or adenosine) and the
allostericmodulator KI-7 (1 μM) alone or in combination. The speciﬁcity
of agonist-mediated responses was evaluated by cell pre-incubation
with the selective A2B AR antagonist MRS1706 (15 nM). When adeno-
sine was used, the pre-treatment medium consisted in a noncomplete
medium containing 20 μM of Ro 20-1724 without ADA. Intracellular
cyclic AMP (cAMP) levels were measured using a competitive protein
binding method [23].2.4. Osteogenic marker expression during MSC differentiation to
osteoblasts: RT-PCR analysis
MSCswere cultured in normal growthmedium and, 24 h later, were
treated with osteogenic medium alone (control), BAY 60-6583 (5 nM),
NECA (100 nM) or KI-7 (1 μM), alone or in combination. Treatments
were repeated every two days, and the expression levels of osteogenic
markers (Runx2, Osterix, ALP and osteocalcin) were quantiﬁed after 5,
15 or 21 days of treatment.
Gene expression was assessed by RT-PCR, as previously described
[24]. In brief, total RNA was extracted from 0, 5, 15 and 21 days of
osteoblast differentiation using the RNeasy® Mini Kit, according to the
manufacturer's instructions. The purity of the RNA samples was
determined by measuring the absorbance at 260/280 nm. Reverse-
transcription was performed with 500 ng of total RNA using i-Script
cDNA synthesis kit. The primers used for the RT-PCR were designed to
span intron/exon boundaries (Table 1); the annealing temperature
used was 55 °C for all the genes. PCR speciﬁcity was determined using
both a melting curve analysis and gel electrophoresis, and the data
were analysed by the standard curve method. mRNA levels for each
sample were normalised against β-actin mRNA levels, and relative
expression was calculated using the Ct value.
2.5. Mineralization assay
MSCs were seeded (3 × 103 cells/cm2) in normal growth medium
and, 24 h later were treated for different days with osteogenic medium
in the absence (control) or in the presence of NECA (100 nM),
BAY 60-6583 (5 nM), KI-7 (500 nM–5 μM), alone or in combination.
The speciﬁcity of agonist-mediated responses was evaluated by
pre-incubation of the cells with selective A2B AR antagonist MRS1706
(15 nM). In addition, the effects of 8-bromoadenosine 3′,5′-cyclic
monophosphate (8-Br-cAMP, 100 nM–10 μM) and forskolin (1 μM), as
activators of cAMP pathway,were evaluated. Treatmentswere repeated
every two days, and the mineralization was quantiﬁed after 9, 15 or
21 days of treatment. The mineralization degree was quantiﬁed using
OsteoImage™ Staining Reagent (Lonza, Milan, Italy), which speciﬁcally
binds to the hydroxyapatite portion of the bone-like nodules deposited
by cells [25,26].
Qualitative measure of the mineralization was also obtained by
alizarin red staining [8]. After treatment with AR agonists, as above
reported, ﬁxed cells were washed once with distilled water and subse-
quently stained with 2% alizarin red S dissolved in distilled water for
5 min. The remaining dye was washed out, and the cells were washed
once more. Finally, the cells were air-dried and images of the stained
cells were captured using a light microscope.
2.6. Cell viability assay (MTS)
MSCs were seeded in 96-well microplates (5000 cells/well) and
cultured in osteogenic medium for 21 days in the absence (control)
or in the presence of NECA (100 nM), KI-7 (1 μM) and the selective
A2B AR antagonist MRS1706 (15 nM), alone or in combination. To
evaluate cell viability, MTS assaywas used following themanufacturer's
instruction (Promega, Milan, Italy).
2.7. IL-6 production
MSCs were cultured in osteogenic medium for 5–21 days in the
absence (control) or in the presence of NECA (100 nM) or BAY
60-6583 (5 nM) alone or in the presence of KI-7 (1 μM). The speciﬁcity
of agonist-mediated responses was evaluated by pre-incubation of the
cells with the selective A2B AR antagonist MRS1706 (15 nM). The levels
of secreted cytokine IL-6 were assayed in the conditioned medium of
cells treated as described above, using ELISA detection kit (R&D Systems
DuoSet, Minneapolis, MN).
Table 1
Primers used for RT-PCR.
Gene Primer nucleotide sequences Product size (base pairs)
Runx2 FOR: 5′-GGCCCTGGTGTTTAAATGGT-3′
REV: 5′-AGGCTGTTTGACGCCATAGT-3′
178 bp
ALP FOR: 5′-CTGCAAGGACATCGCCTATC-3′
REV: 5′-CATCAGTTCTGTTCTTGGGGTA-3′
101 bp
Osterix FOR: 5′-TCCCTGCTTGAGGAGGAAG-3′
REV: 5′-AAAGGTCACTGCCCACAGAG-3′
153 bp
Osteocalcin FOR: 5′-CCTTTGTGTCCAAGCAGGAG-3′
REV: 5′-GTCAGCCAACTCGTCACAGT-3′
151 bp
β-actin FOR: 5′-GCACTCTTCCAGCCTTCCTTCC-3′
REV-5′-GAGCCGCCGATCCACACG-3′
254 bp
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A non-linear multipurpose curve-ﬁtting programme, Graph-Pad
Prism (Version 5.00), was used for data analysis and graphic presenta-
tion. Data are reported as themean±SEMof 3–4 different experiments.
Statistical analyses were performed using a one-way ANOVA study
followed by the Bonferroni test for repeatedmeasurements. Differences
were considered statistically signiﬁcant when P b 0.05.3. Results
3.1. Characterization of KI-7 as A2B AR allosteric modulator in MSC:
cAMP assay
In previous works we identiﬁed and characterized a new class of
N-(indol-3-ylglyoxyl)amide derivatives as the ﬁrst allosteric modula-
tors of A2B ARs [21,22]. Among these derivatives, KI-7 was found to
act as a positive modulator of A2B AR response provided with a high
selectivity towards the other AR subtypes.
Herein, the activity of KI-7 as positive allosteric modulator of A2B
AR was evaluated in MSCs during their spontaneous differentiation
to osteoblasts.
Functional activity of cAMP pathway in MSCs was demonstrated by
the ability of forskolin and cAMP analogue, 8-Br-cAMP, to stimulate
cAMP intracellular accumulation (Fig. 2C and D).
The selective A2B AR agonist BAY 60-6583 (5 nM) stimulated cAMP
accumulation at all differentiation time points, indicating the presence
of functional A2B AR at all stages of osteoblastogenesis (Fig. 1A). When
compared with undifferentiated MSC (day 0), agonist-mediated cAMP
production increased during the time of osteoblastic induction, reaching
the highest levels on days 5 and 9, and then fell back to basal levels on
days 15–21. The drop in agonist-mediated effects at the late stage of
differentiation process may be most likely ascribed to the reduction in
A2B AR protein expression levels in the terminal phase of osteoblast
differentiation, as previously reported [8].
The potency of BAY 60-6583, as derived by agonist concentration–
response curves performed at 5 day differentiation stage, was in the
nanomolar range (EC50 = 6.0 ± 0.5 nM), a value comparable to that
described for the same agonist in transfected cells (Fig. 1B) [22].
Furthermore, BAY 60-6583-mediated cAMP accumulation appeared
to be completely abrogated by the selective A2B AR antagonistMRS1706,
conﬁrming that the effect of this ligandwas speciﬁcallymediated by A2B
AR subtype (Fig. 1C).
Thereafter, the effects of KI-7 on the responses evoked by the A2B AR
agonist BAY 60-6583 were investigated. Both in undifferentiated
(Fig. 1C) and differentiated (5 days, Fig. 1D) MSCs, KI-7, “per se”, did
not signiﬁcantly affect cAMP levels, suggesting that this compound is
not provided with any intrinsic agonist efﬁcacy. Conversely, the same
compound was able to potentiate cAMP accumulation evoked by two
different BAY 60-6583 concentrations (5 and 50 nM) and these effects
were completely counteracted by MRS1706. These data suggest thatKI-7 behaves as positive allosteric modulator of A2B ARs in MSCs, as
well as in transfected cell lines [22].
Interestingly, the shape of time course of cAMPproduction, obtained
in the presence of KI-7, appeared to be quite different with respect
to that observed with the agonist alone. Indeed, a trend towards a
reduction in cAMP production was observed in the late phase of differ-
entiation, but the second messenger's levels still remained high all the
time. These results suggest that the positive allosteric modulation of
A2B AR allows the agonist to signiﬁcantly activate the cAMP pathway
even when the receptor expression is reduced.
It is well known that the nature of the agonist can make a huge dif-
ference in the response to an allosteric compound. Each combination of
orthosteric probe and allosteric ligand could be characterized by unique
properties. Thus, the “probe-dependence” effects of KI-7were evaluated
during the MSC differentiation. As shown in Fig. 2A and B, NECA and
adenosine induced a signiﬁcant increase in cAMP levels that reached a
maximum after 9 days of differentiation and remained unchanged up
to 21 days. The differences in the time course of cAMP production ob-
tained using the nonselective A2B AR agonists NECA and adenosine vs
the selective A2B AR agonist BAY-606583may be due to the contribution
of other AR subtypes. In particular, a great contribution in the cAMP in-
tracellular accumulation may be ascribed to the A2A AR activity, espe-
cially considering that this AR subtype is up-regulated in the terminal
phase of MSC differentiation.
However, in the early phase of differentiation (up to 5 days of differ-
entiation), the effects elicited by both NECA and adenosine were
completely counteracted by the A2B AR antagonist,MRS1706, thus dem-
onstrating that these agonists mainly label A2B ARs in differentiating
MSCs (Fig. 2C and D).
KI-7 caused a signiﬁcant increase in NECA and adenosine mediated
cAMP production at all the differentiation stages (Fig. 2A and B) and
these effects were completely counteracted by the A2B AR antagonist
MRS1706.
In summary, these results demonstrate that KI-7 allosterically
modulates, in a probe-independent manner, the effects elicited by
different classes of A2B AR ligands on cAMP pathway, as demonstrated
in transfected cell lines [22].
3.2. Effect of KI-7 on osteogenicmarker expression duringMSC differentiation
The effects of the A2B AR orthosteric agonists, NECA and BAY
60-6583, and of the positive allostericmodulator, KI-7, on the regulation
of different osteogenic marker expression were evaluated. In detail, the
expression of two pivotal transcription factors that lead cells towards
osteoblast phenotype, Runx2 and Osterix, was ﬁrst evaluated. In paral-
lel, the transcriptions of ALP, that is an early marker of osteoblast differ-
entiation, and of osteocalcin, that appears later concomitantly with
mineralization, were evaluated as markers of later osteoblastogenesis
stage [27–29].
DuringMSC differentiation in osteogenic medium, the expression of
the transcription factors Osterix and Runx2 followed the typical time
course of these gene targets. Runx2mRNApeaked after 15 days of treat-
ment and tended to decrease in the late stage of differentiation (Fig. 3A).
Osterix, a downstream gene of Runx2, was indeed expressed in a later
stage during differentiation and its levels were maintained up to
21 days of the differentiation process (Fig. 3B). Treatment of the cells
with NECA, BAY 60-6583 or KI-7 alone induced a signiﬁcant increase
in mRNA expression of Runx2 and Osterix, at all the differentiation
stages. Moreover, KI-7 was able to signiﬁcantly increase the effects
of both NECA and of the selective A2B AR agonist BAY 60-6583,
demonstrating its positive modulator activity on A2B AR (Fig. 3A and B).
NECA and BAY 60-6583 were also able to potentiate the expression
of both ALP and osteocalcin proteins, and these effects were strongly
increased by KI-7 (Fig. 3C and D). These results demonstrate that KI-7
facilitates the A2B AR agonist-mediated signalling, so as to accelerate
and strength the osteoblast differentiation process.
Fig. 1. Effect of BAY 60-6583 andKI-7 on cAMP accumulation inMSC during differentiation process. (A) UndifferentiatedMSCswere cultured under osteogenicmedium for different times
(0–21 days). At each time, cells were treated for 15 min with 5 nM BAY 60-6583 in the absence or presence of 1 μM KI-7 and then, cAMP production was evaluated. (B) Dose-response
curve of BAY 60-6583 in MSCs, cultured under osteogenic medium for 5 days. (C, D) undifferentiated (C) and 5 day differentiated cells (D) were treated for 15 min with 5–50 nM BAY
60-6583 or with 1 μM KI-7, alone or in combination. Aliquots of cells were treated with 15 nM A2B AR antagonist MRS1706, alone or in combination with the agonists. After ligand
treatments, intracellular cAMP levels were quantiﬁed. The data are expressed as fold of cAMP change versus basal value, which was set to 1, and represent the mean ± SEM
of three different experiments performed in triplicate. *P b 0.05, **P b 0.01, and ***P b 0.001 vs respective basal, set to 1; #P b 0.05, ##P b 0.01, and ###P b 0.001 vs BAY
60-6583; §§P b 0.01, and §§§P b 0.001 vs BAY 60-6583 + KI-7.
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MSC-derived osteoblasts
As A2B AR plays a role in osteoblastogenesis, it was investigated
whether the activation of these receptors by KI-7 and orthosteric
agonists could stimulate matrix mineralization. MSCs, cultured under
osteogenic medium, underwent a spontaneous, time-dependent, min-
eralization. Cell treatment with either NECA or BAY 60-6583 induced a
signiﬁcant increase, to the same extent and in all differentiation stages,
in the mineralization process of MSCs. The presence in the incubation
medium of ADA, which removes endogenous adenosine, did not signif-
icantly affect neither spontaneous nor A2B AR agonist-induced MSC
differentiation, suggesting endogenous adenosine “per se” is not
enough to regulate the differentiation process. The A2B AR agonist
effects were most completely counteracted by cell pre-incubation
with the A2B AR antagonist MRS1706, suggesting that A2B AR is the
major subtype responsible for the induction of mineralization (Fig. 4A,
B and C).
Since the A2B AR mainly signals through cAMP/PKA pathway,
the effects of adenylate cyclase activator, forskolin, and of the
cAMP analogue, 8-Br-cAMP on the induction of mineralization wereevaluated (Fig. 4A,B and C). The results demonstrate that both forskolin
and 8-Br-cAMPwere able to regulate MSC differentiation, with peculiar
effects, dependent on both drug concentration and time of cell expo-
sure. MSC short-time exposure to a low concentration of a cAMP activa-
tor induced a signiﬁcant and marked increase in the mineralization
process. These effects gradually decreased when a high compound con-
centration and/or a long time cell exposure conditions were used. By
the comparison between the data obtained in mineralization studies,
using cAMP modulators and A2B AR ligands, we can speculate that A2B
AR-mediated effects on osteogenesis involve, at least partially, the
cAMP pathway, but this mechanism may not be primary responsible
for the terminal phase of osteoblast maturation.
Treatment of MSCs with KI-7 alone induced a concentration-
dependent increase in osteoblast mineralization at all differentiation
stages (Fig. 5A, B and C), and this effect appeared to be completely
abrogated by cell pre-incubation with the A2B AR antagonist MRS1706.
Interestingly, the effect of KI-7 on the mineralization process was
likewise almost completely abrogated when cells were treated with
ADA, which removes endogenous adenosine (Fig. 5C). These results
suggest that KI-7 potentiates adenosine activity in favouring osteoblast
mineralization trough activation of A2B AR.
Fig. 2. Effect of KI-7 on NECA or adenosine-mediated cAMP accumulation in MSC during differentiation process. (A, B) Undifferentiated MSCs were cultured under osteogenic
medium for different times (0–21 days). At each time, cells were treated with 100 nM NECA (A) or 1 μM Adenosine (B) alone or in combination with 1 μM KI-7 and then,
cAMP levels were quantiﬁed. (C, D) undifferentiated (C) and 5 day differentiated cells (D) were treated for 15 min with 100 nM NECA or 1 μMAdenosine alone or in combination
with 1 μM KI-7. Aliquots of cells were treated with 15 nM A2B AR antagonist MRS1706, alone or in combination with the agonists. Aliquots of cells were treated for 15 min with 1 μM
Forskolin (FK) or 1 μM 8-Br-cAMP. After ligand treatments, intracellular cAMP levels were quantiﬁed. The data are expressed as fold of cAMP change versus basal value, which was set
to 1, and represent the mean ± SEM of three different experiments performed in duplicate. *P b 0.05, **P b 0.01, and ***P b 0.001 vs respective basal, set to 1;##P b 0.01, and
###P b 0.001 vs BAY 60-6583; and §§P b 0.01, and §§§P b 0.001 vs BAY 60-6583 + KI-7.
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agonists on mineralization was then investigated. KI-7 potentiated
osteoblast mineralization evoked by both NECA and BAY 60-6583 in a
concentration-dependent manner at all differentiation stages (Fig. 6A,
B and C), and these effects appeared to be completely counteracted by
the A2B AR antagonist MRS1706. These data conﬁrm that KI-7, acting
as a positive allosteric modulator of A2B AR, favours cell mineralization
resulting from the A2B AR activation. These results were qualitatively
conﬁrmed by alizarin-Red staining of differentiated cells (Fig. 6D and E).
3.4. Effects of A2B AR orthosteric ligands and of KI-7 on osteoblast survival
The effects of the A2B AR orthosteric ligand NECA and of allosteric
modulator KI-7 on survival of MSC cultures, differentiated in osteogenic
medium for 15 or 21 days, were then evaluated. Cell treatment with
NECA or KI-7 induced a signiﬁcant increase in cell viability in both
differentiation stages (Fig. 7A and B). The effects evoked by the two
compounds were almost completely reversed by the A2B AR antagonist
MRS1706, demonstrating the speciﬁc involvement of the A2B AR sub-
type. Moreover, KI-7 induced a signiﬁcant increase in the pro-survivaleffects of the orthosteric agonist. These data suggest that orthosteric
agonists and positive allosteric modulators of A2B AR, in addition to
favouring osteoblast differentiation, play a crucial role in regulating
the viability of differentiated cells.
3.5. Effects of A2B AR orthosteric ligands and of KI-7 on IL-6 release
It is know that activation of A2B AR promotes IL-6 expression in
different cell lines [30–32] and that this cytokine has a role, even if
quite controversial, in the control of osteoblast differentiation [33,
34]. On this basis, we investigated the effects of A2B AR orthosteric
ligands and KI-7 on IL-6 production during all the stages of MSC
differentiation to osteoblasts. In control cells, cultured under osteogenic
medium, IL-6 release signiﬁcantly decreased during the differentiation
process (Fig. 8).
Treatment of the cells for 5 or 9 days with NECA or BAY 60-6583 or
KI-7 favoured the spontaneous decrease in IL-6 production. This effect
was strongly potentiated when NECA or BAY 60-6583 were used in
combination with KI-7. These data suggest that agonist-mediated A2B
AR activation reduces IL-6 production, thus favouring differentiation of
Fig. 3. Effect of NECA and KI-7 on osteogenic marker expression. MSCs were cultured in osteogenic medium for different time (0–21 days), in the absence (control) or in the presence of
100 nMNECA, 5 nMBAY 60-6583 or 1 μMKI-7, alone or in combination. At each time,mRNA expression levels of transcription factors Runx2 (A) andOsterix (B), and of osteogenic protein
markers, ALP (C) and osteocalcin (D)were quantiﬁed by real time PCR. Data are expressed as fold of changes versus basal value (set to 1) and represent themean± SEM of three different
experiments. *P b 0.05; **P b 0.01, and ***P b 0.001 vs basal; #P b 0.05, ##P b 0.01, and ###P b 0.001 vs untreated cells; §P b 0.05, §§P b 0.01, and §§§P b 0.001 vs NECA alone; °°P b 0.01, and
°°°P b 0.001 vs BAY 60-6583 alone.
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tion of A2B AR.
Surprisingly, when the MSC differentiation process was prolonged
to 15 or 21 days, a time corresponding to the late stage of differentia-
tion, NECA, BAY 60-6583 and KI-7 induced a strong increase in IL-6Fig. 4. Effect of A2B AR orthosteric agonists on MSC mineralization. MSCs were cultured for 9 (A
ADA (0.5 U/mL), alone or in combination. Aliquots of cells were treated with Forskolin (1 μM
OsteoImage™ Staining Reagent and ﬂorescence was counted using a plate reader (excitation/
represent the mean ± SEM of three different experiments performed in triplicate. *P b 0.05, **production. In addition, KI-7 was able to potentiate the effects of
orthosteric agonists in both differentiation stages, even if the effect
became signiﬁcant only at 21 days.
Since almost comparable results were obtained using NECA or the se-
lective A2B AR agonist BAY 60-6583, we can conclude that the increase in), 15 (B) or 21 (C) days with 100 nMNECA or 5 nM BAY 60-6583 or MRS1706 (15 nM) or
) or 8-Br-cAMP (100 nM–10 μM). After treatments, cells were stained with ﬂuorescent
emission wavelengths 485/535 nm). Data are expressed as relative ﬂuorescence Unit and
P b 0.01, and ***P b 0.001 vs control; and #P b 0.05, and ##P b 0.001 vs agonist alone.
Fig. 5. Effect of KI-7 onMSCmineralization.MSCswere cultured for 9 (A), 15 (B) or 21 (C) dayswith KI-7 at different concentrations (500 nM–5 μM) in the absence or in thepresence of the
A2B AR antagonist MRS1706 (15 nM) or ADA (0.5 U/mL). After treatments, cells were stained with ﬂuorescent OsteoImage™ Staining Reagent and ﬂorescence was counted using a plate
reader (excitation/emission wavelengths 485/535 nm). Data are expressed as relative ﬂuorescence Unit and represent the mean ± SEM of three different experiments performed in
triplicate. *P b 0.05, ** P b 0.01, and ***P b 0.001 vs control.
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of A2B AR subtype. These data were also conﬁrmed by the demonstration
that NECA-mediated IL-6 release was almost completely counteracted by
cell pre-incubation with the selective A2B AR antagonist MRS1706.
4. Discussion
The identiﬁcation of factors that regulate MSC differentiation into
osteoblasts may be of great interest to understand both normal boneFig. 6. Effect of KI-7 on osteoblast mineralization induced by orthosteric A2B AR agonists. M
(500 nM–5 μM) in the presence of 100 nMNECA or 5 nM BAY 60-6583. In a set of cells, the A
treatments, cellswere stainedwith ﬂuorescent OsteoImage™ Staining Reagent and ﬂorescence
expressed as relative ﬂuorescence Unit and represent themean± SEM of three different exper
##P b 0.01, and ###P b 0.001 vs agonist alone; and §§P b 0.01, and §§§P b 0.001 vs agonist + KI-
red S to visualize mineral nodules, after osteo-induction for 21 days with different ligands, alodevelopment and pathological conditions. A deeper knowledge of
such phenomena may be also helpful in the search for therapeutic
treatments of bone diseases, such as osteoporosis.
Adenosine and its receptors are known to play a fundamental role in
bone homeostasis. Under basal conditions, adenosine concentration in
cells and tissue ﬂuids are low (30 to 300 nM). When cells become
stressed (e.g., during hypoxic events, inﬂammation, tissue injury),
adenosine accumulates at high concentrations (up to 30 μM) in the
extracellular space [35–37] and signals through the activation of all ARSCs were cultured for 9 (A), 15 (B) or 21 (C) days with different KI-7 concentrations
2B AR antagonist MRS1706 (15 nM)was also included in the incubationmedium. After
was counted using a plate reader (excitation/emissionwavelengths 485/535 nm). Data are
iments performed in triplicate. *P b 0.05, **P b 0.01, and ***P b 0.001 vs control; #P b 0.05,
7. D) Representative photograph (10×magniﬁed images) of cultures stained with alizarin
ne and in combination.
Fig. 7. Effect of KI-7 and NECA on differentiated osteoblast viability.MSCs, cultured under osteogenicmedium,were treated for 15 (A) or 21 (B) dayswith 100 nMNECA orwith 1 μMKI-7,
alone or in combination. Aliquots of cells were treatedwith 15 nMA2B AR antagonist MRS1706, alone or in combinationwith NECA or KI-7. After treatments, cell viability was detected by
MTS assay. Thedata are expressed as percentage of cell viability versus control, set to 100%, and represent themean±SEMof threedifferent experiments performed induplicate. *Pb 0.05,
**P b 0.01, and ***P b 0.001 vs control; #P b 0.05, ##P b 0.01, and ###P b 0.001 vs agonist alone; and §P b 0.05, and §§P b 0.01 vs NECA.
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subtypes, the A2B AR is a prime player in the commitment and differen-
tiation of MSCs to osteoblasts: it enhances the three stages of initiation,
maturation, and mineralization, and its activation or over-expression in
undifferentiated cells is sufﬁcient to promote the expression of
osteoblast lineage markers [7–11].
The above ﬁndings suggest that targeting A2B AR with selective
compounds may represent an innovative therapeutic approach in
bone diseases. In the perspective of a systemic use of an orthosteric
agonist of A2B AR, the wide distribution of ARs throughout the body
would increase the risk of adverse effects. For this reason, in the last
years the development of allosteric modulators of ARs has represented
an area of active research [14,15]. Indeed, these compounds mayFig. 8. Effect of A2B AR activation on the release of IL-6 by MSC, during osteogenic
differentiation. MSCs, cultured under osteogenic medium, were treated for different
days with 100 nM NECA or 5 nM BAY 60-6583, alone or in combination with 1 μM KI-7.
Aliquots of cells were pre-incubated with 15 nM MRS 1706 before NECA treatment.
At each time, IL-6 protein levels in medium were quantiﬁed using an ELISA kit.
Data are expressed as pg/mL and represent themean± SEM of two different experiments
performed in triplicate. *P b 0.05, **P b 0.01, and ***P b 0.001 vs control; #P b 0.05, and
##P b 0.01 vs NECA or BAY 60-6583; and §§P b 0.01 vs KI-7.represent a more “physiologic” alternative to orthosteric ligands
thanks to their capability of modulating the interaction between
the receptor and its endogenous ligands. Particularly, positive
allosteric modulators of ARs (compounds potentiating the effects of
endogenous adenosine) can lead to site-speciﬁc and event-speciﬁc
responses mainly in damaged tissues, where adenosine is massively
released. Such a pharmacological activity should be in principle
characterized by less side effects compared with those potentially
caused by orthosteric agonists.
Recently, we have developed and characterized a new class of
1-benzyl-3-ketoindoles as the ﬁrst allosteric modulators of A2B AR, pro-
vided with high efﬁcacy and selectivity towards the other ARs [21,22].
Particularly, we have shown that these compounds are able to increase
efﬁcacy of A2B AR orthosteric agonists in a transfected cell line, by facil-
itating A2B AR–Gs protein coupling, and thus increasing the functional
response of A2B AR agonists on the cAMP signalling pathway. On the
contrary, the same compounds were not able to affect A1, A2A and A3
AR responses, suggesting they may represent useful tools to selectively
target A2B AR.
Herein, we demonstrate that one of these compounds, namely KI-7,
acts as allosteric modulator of A2B AR signalling in MSCs, and exerts a
potent effect in favouring differentiation to osteoblast phenotype of
MSCs in response to A2B AR agonists.
By cAMP functional assays we demonstrate that KI-7, in a probe-
independent manner, potentiated the stimulation of cAMP accumula-
tion evoked by selective A2B AR agonists, through a selective allosteric
modulation of A2B AR subtype, as described in transfected cells [22].
Furthermore, KI-7 induced a signiﬁcant change in the time course of
cAMP production in response to A2B AR agonists: while the functional
response of A2B ARs appeared to gradually decrease in the terminal
phase of MSC differentiation process, in the presence of KI-7 the second
messenger's levels still remained high all the times. From these data we
can speculate that KI-7, through an allosteric modulation of A2B ARs, is
able to increase A2B AR coupling to effector system over all the differen-
tiation time. The allosteric modulator may thus slow down the receptor
switch-off, that is due to the physiological decrease in receptor protein
expression in the late phase of the differentiation process [8].
Moreover, KI-7 showed a great facilitatory effect on the ability
of A2B AR orthosteric agonists in promoting MSC differentiation to
osteoblasts by i) increasing the expression of osteoblast related
genes and ii) accelerating/increasing osteoblast mineralization.
Intriguingly, KI-7 was also able to increase cell mineralization in the
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the effects of endogenous adenosine. It has been demonstrated that ex-
tracellular accumulation of adenosine in non-stressed cell cultures is
not enough to activate any of its receptors and to regulate cell prolifer-
ation and osteogenic differentiation [13]. Accordingly, we demonstrat-
ed that cell treatment with ADA, to remove endogenous adenosine,
did not alter differentiation programme. In the presence of KI-7, the
pro-osteogenic effects of endogenous nucleoside became detectable,
suggesting that this compound potentiates adenosine physiological
responses, without the need of an exogenous agonist. Furthermore,
the selectivity of KI-7 towards A2B AR may ensure that signals evoked
by adenosine through A2B AR activation could get the upper hand on
the effects mediated by the other AR subtypes, causing in turn a forced
commitment of MSC towards osteoblast lineage.
Then, we investigated the mechanism by which A2B ARs regulate
MSC differentiation. The cAMP/PKA pathway has been demonstrated
to play a crucial role in controlling osteogenic process [42,43], also in
response to different Gs-coupled receptors includingA2B ARs and recep-
tors for melatonin and parathyroid hormone (PTH) [11,44–47]. Actual-
ly, how Gs-mediated cAMP signalling regulates MSC development
remains controversial. It has been demonstrated that cAMP stimulation
in MSCs enhances the osteogenic response, while continuous activation
of cAMP in differentiating osteoblasts negatively affects mineralization.
These different effects could be attributed to the cell types which
express Gs-coupled receptors to receive the signal. These data perfectly
agree with our results demonstrating that i) cAMP activators induced a
signiﬁcant and marked increase in the mineralization process within
the ﬁrst differentiation days and ii) these effects gradually decreased
during differentiation time. From these data we can speculate that
cAMP signalling is crucial to prime lineage commitment ofMSC towards
osteoblast phenotype but is not involved in the terminal phase of
osteoblast maturation, as previously suggested [8,11,47,48].
Bone turnover processes are regulated by several hormones, growth
factors and cytokines [49–51]. Among cytokines, it is worth outlining
the role of IL-6 in activating target genes involved in proliferation, differ-
entiation, survival and apoptosis in a variety of cells [52]. Several ﬁnd-
ings indicate that IL-6, even if it has been reported to have
contradictory effects on bone resorption and osteoblast function [34,
53,54], is a key regulator in bone remodelling and is essential for bone
homeostasis. The maintenance of low levels of this cytokine is
required to allow MSC to complete differentiation process [33,55],
while the sustained increase in its levels in the terminal phase ensures
a pro-survival effect on differentiated osteoblasts [56]. On the other
hand, several data demonstrate the cross-talk between purinergic re-
ceptors and cytokines in the regulation of cellular homeostasis. In par-
ticular, A2B AR acts as an eternal clue to modulate the release of IL-6 in
several cells [30–32,57] and cytokine themselves play a role in the con-
trol of AR responses [58–60]. Concerning bone homeostasis, A2B AR has
been identiﬁed as a key regulator of osteoblast differentiation and as
local contributor to regulate bone formation, also through stimulation
of IL-6 release [38].
Based on this evidence, suggesting a functional interplay between
A2B AR and IL-6 in the regulation of bone homeostasis, we investigated
the effects of A2B AR agonists on IL-6 release, and in parallel on the
viability of MSCs during differentiation program. We demonstrate that
IL-6 levels are down-regulated under spontaneous osteoblast differenti-
ation of MSCs. The A2B AR activation by orthosteric agonists and by the
positive allosteric modulator KI-7, either each alone and much more in
combination, potentiated the physiological decrease of IL-6 release
during the differentiation program. Based on these data, we speculate
that the reduction of IL-6 levels, induced by the activation of A2B AR,
may represent one of the mechanisms by which adenosine accelerates
MSC differentiation.
Intriguingly, at the terminal phase of differentiation process, A2B AR
agonists caused a sustained increase in IL-6 release and this effect was
raised by KI-7. In parallel, a signiﬁcant increase in cell viability wasobserved. Since the effects elicited by A2B AR agonists were completely
abrogated by the selective A2B AR antagonist MRS1706, we can most
likely ascertain that they are speciﬁcally mediated by A2B AR and do
not involve the other AR subtypes.
Noticeably, the increase in IL-6 levels did not correlate with the pro-
duction of intracellular cAMP. Based on these evidences, we can specu-
late that A2B ARmediates IL-6 release through the activation of different
intracellular signalling pathways, depending on the stage of cell differ-
entiation (i.e., undifferentiated MSCs or differentiating osteoblasts). In
this respect, in cardiac ﬁbroblasts and in pituitary folliculostellate cells
it has been demonstrated that the A2B AR induce IL-6 release via PKC-
p38 signalling pathway [61,62]. Studies are in progress to investigate
the different signal pathways involved in A2B AR-mediated control of
IL-6 release, especially in the late phase of differentiation process
when cAMP levels in response to A2B AR agonists fall-down.
These results suggest that, depending on cell phenotype, A2B
ARs have distinct effects on IL-6 release, with different physiological
implications: in the ﬁrst stage of differentiation, it would reduce IL-6
levels and favour MSC commitment to osteoblasts; in terminal
phases, it would promote IL-6 release and rescue differentiated
cells from physiological death. IL-6 restoration induced by A2B AR ag-
onists in differentiatedMSCs should have a great therapeutic impact,
by enhancing long-term ability of MSC for tissue repair and regener-
ation. In this context, the development of positive allosteric modula-
tors of A2B AR, capable to differentiate MSC and ensure expression
of soluble immunosuppressive factors, may represent a goal for
regenerative medicine in bone disease.
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